What's in Seldar Pharma, Inc.'s pipeline?

Seldar Pharma, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Seldar Pharma, Inc.'s portfolio?

Top competitors by shared drug class: AmMax Bio, Inc., Aronora, Inc., Astellas Pharma Europe B.V., Astellas Pharma Global Development, Inc., Astellas Pharma Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/seldar-pharma-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Seldar Pharma, Inc. — Portfolio Competitive Intelligence Brief

Seldar Pharma, Inc. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AmMax Bio, Inc. · 1 shared drug class
Aronora, Inc. · 1 shared drug class
Astellas Pharma Europe B.V. · 1 shared drug class
Astellas Pharma Global Development, Inc. · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
AstraZeneca · 1 shared drug class
Axikin Pharmaceuticals, Inc. · 1 shared drug class
Addpharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seldar Pharma, Inc.:

Cite this brief

Drug Landscape (2026). Seldar Pharma, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seldar-pharma-inc. Accessed 2026-05-15.